Thus, these results demonstrate that lenalidomide treatment affects transcriptional regulators and the Akt signal integrator within memory CD3+ CD8+ T cell populations, resulting in enhanced anti-tumor activities of XBP1 antigen-specific CTL. Here, CD8A is linked to neoplasm.